VR Logo

Unrated

ITI Pharma and Healthcare Fund - Direct Plan


Suitability:

This is a fund that invests mainly in shares of pharmaceutical and healthcare companies.

We believe that investors should avoid funds that have a narrowly defined investment mandate such as this one. Instead, they should invest in flexi-cap funds which provide complete freedom to the fund management team to invest in companies from which it expects maximum gains.

But if you do invest, you must do so only through the SIP route. Click here to read a primer on SIP investing.

Warning: Do not invest in this, or any other pharma sector fund, if you need to redeem your investment in less than seven years.

Taxability of earnings:

Capital gains

  • If the mutual fund units are sold after 1 year from the date of investment, gains upto Rs 1 lakh in a financial year are exempt from tax. Gains over Rs 1 lakh are taxed at the rate of 10%.
  • If the mutual fund units are sold within 1 year from the date of investment, entire amount of gain is taxed at the rate of 15%.
  • No tax is to be paid as long as you continue to hold the units.

Dividends

  • Dividends are added to the income of the investors and taxed according to their respective tax slabs. Further, if an investor's dividend income exceeds Rs. 5,000 in a financial year, the fund house also deducts a TDS of 10% before distributing the dividend.

Read more

ajax-loader
Please wait...

ajax-loader
Please wait...

(₹)
cal
cal

ajax-loader
Please wait...

Trailing Returns (%)

YTD 1-Day 1-W 1-M 3-M 6-M 1-Y 3-Y 5-Y 7-Y 10-Y
Fund -5.03 0.56 -3.69 -0.41 -- -- -- -- -- -- --
S&P BSE Healthcare TRI -8.38 0.78 -4.62 -3.51 -- -- -- -- -- -- --
Equity: Sectoral-Pharma -7.00 0.58 -4.04 -2.09 -- -- -- -- -- -- --
Rank within category 1 6 2 1 -- -- -- -- -- -- --
Number of funds in category 10 10 10 10 9 9 9 7 4 3 0

As on 25-Jan-2022

Peer Comparison

Fund name Rating Launch Date 1-Year Return 3-Year Return 5-Year Return Expense Ratio Assets (Cr)
ITI Pharma and Healthcare Fund - Direct Plan
Unrated
Nov-21 -- -- -- 0.31% 179
Nippon India Pharma Fund - Direct Plan
Unrated
Jan-13 13.34 24.78 17.80 1.03% 5,397
ICICI Prudential Pharma Healthcare And Diagnostics (P.H.D) Fund - Direct Plan  | Invest Now
Unrated
Jul-18 12.77 27.47 -- 1.16% 2,964
SBI Healthcare Opportunities Fund - Direct Plan  | Invest Online
Unrated
Jan-13 10.87 23.35 12.05 1.05% 1,943
Mirae Asset Healthcare Fund - Direct Plan  | Invest Online
Unrated
Jul-18 21.71 31.32 -- 0.49% 1,935

Best & Worst Performance

Best Performance Worst Performance
Return (%) Period Return (%) Period
Week 4.87 24-Dec-2021 - 31-Dec-2021 -3.78 14-Jan-2022 - 21-Jan-2022
Month 5.55 17-Dec-2021 - 17-Jan-2022 -2.94 18-Nov-2021 - 20-Dec-2021
Quarter -- - -- -
Year -- - -- -

Risk Measures (%)

Mean Std Dev Sharpe Sortino Beta Alpha
Fund -- -- -- -- -- --
S&P BSE Healthcare TRI* 24.04 21.45 0.95 1.89 -- --
Equity: Sectoral-Pharma* 28.54 19.29 1.30 2.68 0.87 7.06
Rank within category -- -- -- -- -- --
Number of funds in category -- -- -- -- -- --

The Risk Measures have been calculated using calendar month returns for the last three years.

As on

* As on 31-Dec-2021

Asset Allocation (%)

ajax-loader
Please wait...

Concentration & Valuation

Number of Stocks 25
Top 10 Stocks (%) 69.43
Top 5 Stocks (%) 48.23
Top 3 Sectors (%) 89.40
Portfolio P/B Ratio 4.59
Portfolio P/E Ratio 32.88

Portfolio Aggregates

Fund Category
Average Mkt Cap (Rs Cr) 49,693 57,163
Giant (%) 19.75 16.30
Large (%) 31.53 39.85
Mid (%) 42.83 37.16
Small (%) 5.88 6.60
Tiny (%) -- 0.69

Value Research Fund Style

Sector Allocation vis-à-vis Category

ajax-loader
Please wait...

Top Holdings

Company Sector P/E 3Y High 3Y Low % Assets
equal Sun Pharmaceutical Industries Healthcare 31.04 17.66 16.85 17.66
equal Lupin Healthcare -- 9.74 9.70 9.74
equal Dr. Reddy's Lab Healthcare 37.39 9.91 9.72 9.72
equal Divi's Laboratories Healthcare 50.42 6.71 6.01 6.01
equal Natco Pharma Healthcare 63.01 5.10 5.05 5.10
equal Torrent Pharmaceuticals Healthcare 43.89 4.94 4.90 4.94
equal Alembic Pharmaceuticals Healthcare 16.94 5.09 4.73 4.73
up Glaxosmithkline Pharma Healthcare 56.42 4.48 2.89 4.48
up Cipla Healthcare 28.40 4.26 3.03 4.26
equal Suven Pharmaceuticals Healthcare 33.00 2.95 2.79 2.79
equal Sanofi India Healthcare 16.73 2.89 2.68 2.68
equal Ajanta Pharma Healthcare 26.91 2.01 2.00 2.01
equal Max Financial Services Financial 101.81 2.02 1.97 1.97
up Alembic Healthcare 7.91 1.94 1.45 1.94
up SBI Life Insurance Company Insurance 89.80 1.93 1.04 1.93
up ICICI Lombard General Insurance Company Insurance 52.30 1.33 0.94 1.33
up Aster DM Healthcare Healthcare 26.24 1.28 0.93 1.28
new JB Chemicals & Pharma Healthcare 28.69 1.08 0.00 1.08
new Syngene International Healthcare 56.20 1.04 0.00 1.04
new Alkem Laboratories Healthcare 24.24 1.01 0.00 1.01
equal FDC Healthcare 16.35 0.99 0.98 0.98
equal Ipca Laboratories Healthcare 26.85 0.94 0.91 0.91
new Indoco Remedies Healthcare 28.44 0.81 0.00 0.81
equal Max Healthcare Institute Healthcare 81.58 0.75 0.69 0.75
new Hester Biosciences Healthcare 44.49 0.25 0.00 0.25

up down equal Indicates an increase or decrease or no change in holding since last portfolio
new Indicates a new holding since last portfolio

As on 31-Dec-2021

Fund Manager

— Pradeep Gokhale since 18-Oct-2021

Education: Mr Pradeep is a qualified Chartered Accountant from Institute of Chartered Accountants of India, New Delhi and a Chartered Financial Analyst from CFA Institute – USA.

Experience: Prior to joining ITI Asset Management Ltd., he has worked with Tata Asset Management Ltd., CARE Ratings Ltd., Bombay Dyeing, Tata International and Lubrizol India Ltd. He has over 23 years of extensive experience in Fund Management, Equity Research, Credit Evaluation and Ratings. During his 15-year stint at Tata Asset Management Ltd., he managed a broad spectrum of schemes across large cap (Tata Large Cap Fund), multi cap (Tata Large and Midcap Fund, Tata India Tax Savings Fund and the equity portion of Tata Hybrid Equity Fund), offshore fund (Tata India Offshore Opportunities Fund) and thematic funds (Tata Ethical Fund) with assets under management exceeding Rs. 5,000 crores. He was responsible for heading the equity research function and also for tracking various sectors and a wide variety of stocks. On the other hand, at CARE, he took care of multiple ratings and advisory assignments of companies across manufacturing, financial services and other services sectors.

Funds Managed:

— Rohan Korde since 18-Oct-2021

Education: Mr. Korde is a Masters in Management Studies (Finance), Bachelor of Commerce

Experience: Prior to joining Asset Management Limited, he has worked with BOB Capital Markets as Vice President Research, Prabhudas Lilladher as Vice President Research and Anand Rathi Share & Stock Brokers as Vice President Research.

Funds Managed:


0.56%

Change from previous, NAV as on 25-Jan-2022

Growth: ₹ 9.7824

IDCW: ₹ 9.7824


Investment Strategy

The scheme seeks to generate long term capital appreciation through investing in equity and equity related securities of companies engaged in Pharma and Healthcare.

Investment Details

Min. Investment (₹) 5,000
Min. Addl Investment (₹) 1,000
Min. SIP Investment (₹) 500
Min. No of Cheques 12
Min. Withdrawal (₹) 1,000
Min. Balance (₹) --
Lock-in Period Not Applicable
Exit Load 1% for redemption within 365 days

Basic Details

Fund House: ITI Mutual Fund
Launch Date: 08-Nov-2021
Return Since Launch: -2.18%
Benchmark: NIFTY Healthcare TRI.
Riskometer: Very High
Type: Open-ended
Assets: ₹ 179 Cr (As on 31-Dec-2021)
Expense: 0.31% (As on 31-Dec-2021)
Risk Grade: --
Return Grade: --
Turnover: --

Contact Information

AMC: ITI Asset Management Ltd.

Address: ITI Asset Mangement Limited, ITI House, Building no. 36, Dr. R. K. Shirodkar Marg, Parel, Mumbai - 400012

Phone: 1800-266-9603 / 022-66214999

Email: [email protected]

Website: http://www.itiamc.com

Registrar & Transfer Agent: KFin Technologies Pvt Ltd.

Address: 303, Vamsee Estates, Opp. Big Bazaar, Ameerpet, Hyderabad - 500016

Phone: 040-44857874

Email: [email protected]

Website: www.karvymfs.com

Upcoming Video

Investors' Hangout

How to choose the best hybrid fund?

DateFriday, 04-Feb-2022
Time12:30 PM - 01:00 PM

attending You have reserved a spot